Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Veltuzumab in CD20+ NHL or CLL
NCT00546793Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2008
- Primary completion
- Mar 2013
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of veltuzumab in Non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), sponsored by Gilead Sciences. Primary endpoint: Safety/tolerability at 2 years. Started Jan 2008; status: completed.
02
Drugs
veltuzumab
03
Conditions
Non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00546793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00546793.